The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced the opening of its Therapeutic Pipeline Program. This newly created funding mechanism invites research proposals from industry and academic investigators to drive pre-clinical and clinical Parkinson’s disease drug development.

MJFF has committed up to $14 million in funding toward three research programs, which include the Therapeutic Pipeline Program, Rapid Response Innovation Awards and Target Validation. These programs comprise The Edmond J. Safra Core Programs for PD Research, established in 2008 in honor of the late well-known international banker and philanthropist.

“We’ve updated our annual funding initiatives to streamline processes and support our goal of bringing new treatments to market faster,” said Sonal Das, PhD, associate director of research programs at MJFF. “We’re aiming to cut even more red tape out of our application procedures by allowing successful projects to continue through multiple phases of the drug development process without needing to pause and reapply for funding at every stage of the pipeline.”

Learn more about these funding opportunities and read the Foundation’s announcement.